LPCAT1 Inhibitors are a specialized class of chemical compounds designed to target and inhibit the activity of Lysophosphatidylcholine Acyltransferase 1 (LPCAT1), an enzyme that plays a critical role in phospholipid metabolism. LPCAT1 is responsible for catalyzing the conversion of lysophosphatidylcholine (LPC) into phosphatidylcholine (PC) by incorporating a fatty acyl group into the LPC molecule. This enzyme is essential in maintaining the balance of phospholipids within cell membranes, which are crucial for membrane structure, fluidity, and function. LPCAT1 is particularly important in tissues with high membrane turnover or those requiring rapid remodeling of lipid components, such as the lungs, where it contributes to the production of surfactant, a substance that reduces surface tension and prevents lung collapse.
Inhibition of LPCAT1 offers researchers a valuable tool for studying the broader implications of phospholipid metabolism and its impact on cellular processes. By inhibiting LPCAT1, scientists can explore how disruptions in phospholipid biosynthesis affect membrane dynamics, cellular signaling pathways, and the overall homeostasis of lipid composition within cells. LPCAT1 inhibitors are particularly useful in research focused on understanding how alterations in membrane lipid composition can influence cell behavior, such as changes in membrane permeability, signaling receptor localization, and interactions with extracellular molecules. Additionally, these inhibitors allow for the investigation of LPCAT1's role in specific biological processes, such as lipid droplet formation, energy storage, and lipid signaling pathways. The availability of LPCAT1 inhibitors enables detailed exploration of these processes, contributing to a deeper understanding of lipid metabolism and its significance in various physiological contexts.
SEE ALSO...
Items 1 to 10 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus inhibits mTOR signaling, which could downregulate LPCAT2 expression as part of a broader effect on lipid metabolism. | ||||||
Avasimibe | 166518-60-1 | sc-364315 sc-364315A sc-364315B sc-364315C | 10 mg 50 mg 500 mg 1 g | $107.00 $413.00 $2040.00 $3060.00 | 1 | |
Originally developed as an ACAT inhibitor for cholesterol metabolism, it has been shown to affect phospholipid metabolism and could potentially influence LPCAT (lysophosphatidylcholine acyltransferases) activity. | ||||||
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $45.00 $56.00 $85.00 $3193.00 $4726.00 | 4 | |
Quinacrine is an antimalarial drug that has been found to inhibit LPCAT1 activity. It blocks the acyltransferase function of LPCAT1, leading to decreased PC synthesis. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
Dactolisib is a dual PI3K/mTOR inhibitor, potentially affecting LPCAT2 expression by altering lipid synthesis pathways. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Probenecid has been reported to inhibit LPCAT1, leading to altered lipid metabolism. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases and may influence LPCAT2 expression by modulating signal transduction pathways. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
While primarily a PPARα agonist used in hyperlipidemia, fenofibrate can indirectly affect lipid metabolic pathways, potentially influencing LPCAT (lysophosphatidylcholine acyltransferases) activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone is a PPARγ agonist, which might downregulate LPCAT2 expression through effects on lipid metabolism genes. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, potentially affecting LPCAT2 expression by inducing ER stress and the unfolded protein response. | ||||||
Miltefosine | 58066-85-6 | sc-203135 | 50 mg | $79.00 | 8 | |
An alkylphosphocholine drug that impacts phospholipid metabolism and could indirectly affect LPCAT (lysophosphatidylcholine acyltransferases) function. | ||||||